Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Clinical efficacy and safety of vortioxetine as an adjuvant drug for patients with bipolar depression.
J Zhejiang Univ Sci B
January 2025
Department of Psychiatry, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Objectives: Whether vortioxetine has a utility as an adjuvant drug in the treatment of bipolar depression remains controversial. This study aimed to validate the efficacy and safety of vortioxetine in bipolar depression.
Methods: Patients with bipolar Ⅱ depression were enrolled in this prospective, two-center, randomized, 12-week pilot trial.
Longitudinal Treatment Patterns of Chorea in North American Patients with Huntington's Disease: Data from Enroll-HD.
Neurol Ther
January 2025
Health Economics and Outcomes Research, Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, CA, 92130, USA.
Introduction: Chorea is the primary manifestation of Huntington's disease. Different clinicians pursue varied approaches to chorea management, and real-world evidence describing them is needed. The objective of this study was to assess the presence and severity of chorea, chorea pharmacotherapy, and treatment practice, and patterns in a large natural-history cohort with Huntington's disease.
View Article and Find Full Text PDFPhysicians' and patients' perceived risks of chronic pain medication and co-medications in Quebec, Canada: a cross-sectional study.
BMC Prim Care
January 2025
Département des sciences de la santé, Université du Québec en Abitibi-Témiscamingue (UQAT), Rouyn-Noranda, Québec, Canada.
Background: The risks associated with medications and co-medications for chronic pain (CP) can influence a physician's choice of drugs and dosages, as well as a patient's adherence to the medication. High-quality care requires patients to participate in medication decisions. This study aimed to compare perceived risks of medications and co-medications between physicians and persons living with CP.
View Article and Find Full Text PDFEffects of lithium carbonate combined with olanzapine on glucose and lipid metabolism in the treatment of bipolar disorder and gender differences.
Pak J Pharm Sci
January 2025
Department of Psychiatry, the Fifth People's Hospital of Luoyang, Luoyang City, Henan Province.
To explore the effect of lithium carbonate combined with olanzapine on glucose and lipid metabolism, as well as gender differences in treating bipolar disorder (BD). 110 BD patients admitted to the Fifth People's Hospital of Luoyang from February 2022 to January 2024 were retrospectively included in the study. Patients were categorized into two groups based on treatment: The single group (lithium carbonate, n = 50) and the coalition group (lithium carbonate + olanzapine, n=60).
View Article and Find Full Text PDFTherapeutic effects of chiglitazar combined with Rosa roxburghii Tratt. in inpatients with antipsychotic-induced metabolic syndrome.
Pak J Pharm Sci
January 2025
Department of Psychiatry, Wenzhou Seventh People's Hospital, Wenzhou, China.
The objective of this study was to evaluate the therapeutic effects of Chiglitazar combined with Rosa roxburghii Tratt (RRT) in inpatients diagnosed with psychiatric disorders and antipsychotic-induced metabolic syndrome (MetS).100 cases were included and divided into the Siglitazar group (n=50) and the Siglitazar + RRT group (n=50) Anthropometric measurements, lipid and glucose metabolism indicators, inflammatory markers and PANSS scores were assessed at baseline, 8 weeks and 12 weeks post-treatment. Both treatment groups exhibited significant reductions in waist circumference and improvements in lipid profiles and glucose metabolism indicators over the 12-week study period.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!